Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Roth Capital Initiates Coverage On Newly Listed Unicycive

Roth Capital initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and $13.50 price target.  Analyst Elemer Piros says that the Company could submit…
byVandana Singh
August 9, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Roth Capital initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and $13.50 price target. 
  • Analyst Elemer Piros says that the Company could submit a marketing application to the FDA for Renasorb to treat hyperphosphatemia in chronic kidney disease, or CKD, in “about a year.”
  • The analyst also believes that Renasorb has the potential to become “a dominant player in the kidney disease market.”
  • Unicycive started trading on NASDAQ in July. It offered 5 million units at $5/unit.  
  • Price Action: UNCY shares closed up 14% at $3.05 on Monday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts